Topics

pharmaceuticals
“They Only Silence the Truth”: COVID-19 retractions and the politicization of science
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Canary in a (Post) Covid World: Money, Fear, and Power
Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients
Cardiac Findings in COVID-19 Patients Treated with HAZDPac
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
Covid-19 Has Turned Public Health Into a Lethal, Patient-Killing Experimental Endeavor
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19)
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
HCQ for COVID-19: 412 studies from 8,590 scientists 529,060 patients in 58 countries
HCQ for COVID-19: real-time meta analysis of 368 studies
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients
Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Ivermectin Could Have Saved Millions of Lives, Why Was It Suppressed
Largest Statistically Significant Study by 6,200 Multi-Country Physicians on COVID-19 Uncovers Treatment Patterns and Puts Pandemic in Context
Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic
Open Knowledge Commons versus Privatized Gain in a Fractured Information Ecology: Lessons from COVID-19 for the Future of Sustainability
Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients
Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities
Role of hydroxychloroquine in multidrug treatment of COVID-19
The Key to Defeating COVID-19 Already Exists. We Need to Start Using It
The Worldwide Corona Crisis, Global Coup d’Etat Against Humanity
Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial
Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2
VAERS deaths attributed to COVID-19 vaccines as of June 2021
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials
1032